Medtronic declares cash dividend for Q3 FY 2026 – Dec 4, 2025
Medtronic plc’s board of directors made a significant decision on Thursday, December 4, 2025, by approving a cash dividend for the third quarter of fiscal year 2026 valued at $0.71 for each ordinary share. This announcement is in line with the company’s previous statement regarding a dividend increase made back in May 2025. Medtronic has a long-standing reputation as a component of the S&P 500 Dividend Aristocrats index, as it has consistently raised its annual dividend payout for the last 48 years in a row. Shareholders of record as of the close of business on December 26, 2025, are eligible to receive this dividend payment on January 16, 2026.
Medtronic, headquartered in Galway, Ireland, is a global healthcare technology leader that takes a bold approach to tackle the most pressing health challenges facing society. With a dedicated team of over 95,000 individuals spread across more than 150 countries, Medtronic’s mission is to relieve pain, restore health, and extend life. Their wide range of technologies and therapies cater to 70 different health conditions, covering areas such as cardiac devices, surgical robotics, insulin pumps, surgical tools, and patient monitoring systems. Fueled by their diverse expertise, unquenchable curiosity, and commitment to aiding those in need, Medtronic develops innovative technologies that impact the lives of two individuals every second, every minute, every day. The company is dedicated to improving the quality of care, prioritizing people-centered experiences, and enhancing outcomes across the globe. Medtronic’s relentless pursuit of excellence embodies their core philosophy of “engineering the extraordinary.”
As with any forward-looking statements, there are inherent risks and uncertainties associated with Medtronic’s projections, as outlined in their periodic filings with the Securities and Exchange Commission. Actual results may deviate from expected outcomes due to various factors influencing the market and business environment. For further information on Medtronic and their activities, readers are encouraged to visit www.Medtronic.com and engage with Medtronic’s updates on LinkedIn.
In conclusion, Medtronic’s recent announcement of a cash dividend for the third quarter of fiscal year 2026 underscores the company’s commitment to rewarding its shareholders and maintaining a financially robust position in the market. By consistently enhancing their offerings and expanding their impact globally, Medtronic continues to be a frontrunner in the healthcare technology sector, driving positive change and innovation in the industry.